



**The ACME Laboratories Ltd.**

MANUFACTURERS OF ETHICAL DRUGS & MEDICINES

ISO 9001: 2015 CERTIFIED COMPANY

Office Copy

Ref. No. ACME /CA/CS/2021/0137

15 December 2021

**The Chairman**

Bangladesh Securities and Exchange Commission  
Securities Commission Bhaban  
E-C/6, Agargaon,  
Sher-e-Bangla Nagar Administrative Area,  
Dhaka-1207.

**Subject: Audited Status Report on utilization of Initial Public Offering Proceeds for the Month ended 30 November 2021 of The ACME Laboratories Ltd.**

Dear Sir,

In compliance with the clause 3 & 4 of Part-C of the Letter of Consent vide no. BSEC/CI/BB-03/2014/143; dated: 15 March 2016 accorded by your esteemed organization, we are pleased to enclose herewith the Audited Status Report (as per revised format) on utilization of Initial Public Offering Proceeds for the Month ended 30 November 2021 of The ACME Laboratories Ltd. duly authenticated by the Board of Directors in its 137<sup>th</sup> Meeting held on 14 December 2021 for your kind perusal and record please.

Thanking you and assuring of our best attention for all the time to come.

**Mizanur Rahman Sinha**  
Managing Director

**Enclosure:** As stated above

Copy to: 01. The Managing Director, Dhaka Stock Exchange Limited.  
02. The Managing Director, Chittagong Stock Exchange Limited.  
03. The Chief Executive Officer, ICB Capital Management Limited.



**Corporate Office:**

**Court de la ACME**

1/4 Kallayanpur, Mirpur Road

Dhaka-1207, Bangladesh.

Phone : +88-02-9004194-6

Fax : +88-02-9016872

E-mail : headoffice@acmeglobal.com

[www.acmeglobal.com](http://www.acmeglobal.com)

**Plant:**

Dhamrai, Dhaka, Bangladesh.

Phone : +88-02-7730881-2

+88-02-7730816-7, 7730142

Fax : +88-02-7730141

E-mail : plant@acmeglobal.com

# Auditors' Report

## Name of Client

**The ACME Laboratories Ltd.**  
Utilization of IPO Proceeds  
for the month ended 30 November 2021



**Registered Office:** AHSANDELL, 2/A, Mymensingh Road (2nd Floor), Shahbag, Dhaka-1000, Bangladesh.  
Tel: +08802-966-0944, +8802-966-5095, Cell: +8801711-106302, +8801534-130750.  
E-mail: pinaki\_co@yahoo.com website: www.pinaki.com.bd

## **AUDITORS' REPORT**

*on*

### **Utilization of IPO Proceeds**

We have audited the annexed Statement of Initial Public Offering (IPO) Proceeds Utilization of The ACME Laboratories Ltd. for the month ended 30 November 2021.

#### **Management's Responsibility for the IPO proceeds Utilization**

Management is responsible for the preparation and fair presentation of these IPO proceeds utilization statement in accordance with Bangladesh Securities and Exchange Commission Rules 1987, Condition laid down in clause 3 & 4 of PART-C of consent letter # BSEC/CI/BB-03/2014/143, Dated March 15, 2016 and other applicable laws and regulations.

#### **Auditor's Responsibility**

Our responsibility is to express an independent opinion on these Initial Public Offering (IPO) proceeds utilization statement based on our audit. We conducted our audit in accordance with International Standards on Auditing (ISA), Bangladesh Securities and Exchange Commission Rules 1987, Condition laid down in clause 3 & 4 of PART-C of consent letter # BSEC/CI/BB-03/2014/143, Dated March 15, 2016 and other applicable laws and regulations.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

#### **Opinion**

In our Opinion, the Statement of Initial Public Offering (IPO) Proceeds Utilization, Prepared in accordance with Bangladesh Securities and Exchange Commission Rules 1987 and Condition laid down in clause 3 & 4 of PART-C of consent letter # BSEC/CI/BB-03/2014/143, Dated March 15, 2016 gives a true and fair view of the statement for the month ended 30 November 2021 and comply with the resolution of 42<sup>nd</sup> and 44<sup>th</sup> AGM of the company.

#### **As per TOR, We draw attention to the following matter:**


1. The Company has started commercial operation of Steroid and Hormone project in the month of June 2019, which has been completed within the time limit approved by the shareholders in its 42<sup>nd</sup> AGM. Total project cost of BDT 1,660,591,186 is generated from the IPO fund.

2. The Company has started commercial operation of Penicillin project in the month of June 2019, which has been completed within the time limit approved by the shareholders in its 42<sup>nd</sup> AGM. Total project cost of BDT 400,000,000 is generated from the IPO fund.
3. The Company has also utilized accumulative amount of Tk. 582,609,775 up to 30 November 2021 in respect of API Project. During the month of November 2021, an amount of Tk. 3,283,760 has been utilized out of IPO fund in respect of Active Pharmaceuticals Ingredients (API) Project.

**We also state that:**

- a) IPO proceeds of Steroid and Hormone Project as well as Penicillin Project have been utilized for the purposes as specified in the resolution of 42<sup>nd</sup> AGM of the company;
- b) IPO proceeds have been utilized in line with the conditions of the BSEC's consent letter for the IPO;
- c) API project, for which IPO fund was raised, will be completed within the time frame as specified in the resolution of 42<sup>nd</sup> AGM of the company.
- d) Utilization of IPO proceeds is accurate for the purpose of the company as mentioned in the resolution of 42<sup>nd</sup> and 44<sup>th</sup> AGM of the company.
- e) Audit statement has been made on verification of all necessary documents/papers/vouchers in support of utilization of IPO proceeds making reconciliation with bank statements.

Dhaka  
Date: 14 December 2021

  
**Pinaki Das, FCA**  
Senior Partner  
ICAB Enrol. No: 151  
**Pinaki & Company**  
Chartered Accountants

**Report on Utilization of IPO Proceeds**  
For the Month of November 2021

(The ACME Laboratories Ltd.)

BDT 4,095,015,601 (Net of foreign currency conversion loss)

31 April 2018

11 April 2018 to 31 April 2018

As stated in time columns

Name of the Company

Amount (BDT) of capital raised through IPO

Date of Closure of Subscription

Proceeds Received Date

Last Date of Full Utilization of IPO Fund as per 40th AGM/42nd AGM

S.L.	Purpose mentioned in the 40th AGM/42nd AGM	Time Line	Cost Breakdown	Amount as per			During the Month	Status of Utilization		Total unutilized amount	Unutilized %	Remarks
				40th AGM	42nd AGM	44th AGM		Total Utilized Amount	Utilized %			
1	Seed and Hormone Project	Within 2 years of receiving IPO fund, i.e. 2018	Civil Construction	335,800,000	334,934,878	334,934,878	334,934,878	334,934,878	100.00%	-	0.00%	
			Machinery & Equipment	598,600,000	933,900,000	933,900,000	933,900,000	933,900,000	100.00%	-	0.00%	
			Utility	349,600,000	353,700,000	353,700,000	353,700,000	353,700,000	100.00%	-	0.00%	
			Warehouse	39,500,000	21,986,000	21,986,000	21,986,000	21,986,000	100.00%	-	0.00%	
			Vehicle	5,000,000	5,000,000	5,000,000	5,000,000	5,000,000	100.00%	-	0.00%	
2	Penicillin Project	Within the month of March 2018	Consultancy fee	26,300,000	1,200,000	1,200,000	1,200,000	1,200,000	100.00%	-	0.00%	
			Contingencies	13,200,000	9,870,308	9,870,308	9,870,308	9,870,308	100.00%	-	0.00%	
			Sub Total	1,358,000,000	1,660,591,186	1,660,591,186	1,660,591,186	1,660,591,186	100.00%	-	0.00%	Re-arrangement of Utilization Plan has been approved in 42nd and 44th AGM as on 5 December 2018 & 10 December 2020 and IPO Utilization Proceeds are certified by N/A, Pinaki and Company, Chartered Accountants
			Civil Construction	116,000,000	142,922,303	142,922,303	142,922,303	142,922,303	100.00%	-	0.00%	
			Machinery & Equipment	332,299,520	79,768,602	79,768,602	79,768,602	79,768,602	100.00%	-	0.00%	
3	Active Pharmaceuticals Ingredients (API)	Within 2-3 years after getting permission from the Ministry of Industries	Utility	117,154,000	146,345,797	146,345,797	146,345,797	146,345,797	100.00%	-	0.00%	
			Warehouse	20,582,700	21,641,545	21,641,545	21,641,545	21,641,545	100.00%	-	0.00%	
			Vehicle	3,000,000	2,901,503	2,901,503	2,901,503	2,901,503	100.00%	-	0.00%	
			Consultancy fee	5,963,780	1,420,250	1,420,250	1,420,250	1,420,250	100.00%	-	0.00%	
			Contingencies	5,000,000	5,000,000	5,000,000	5,000,000	5,000,000	100.00%	-	0.00%	
4	Repayment of Bank Borrowing at 40th AGM	Within 2-3 years after getting permission from the Ministry of Industries	Sub Total	400,000,000	400,000,000	400,000,000	400,000,000	400,000,000	100.00%	-	0.00%	
			Civil Construction	347,860,000	355,637,304	606,132,545	579,326,015	582,609,775	96.12%	23,522,770	3.88%	
			Machinery & Equipment	493,000,000	250,495,241	-	-	-	0.00%	-	0.00%	
			Utility	409,400,000	-	-	-	-	0.00%	-	0.00%	
			Warehouse	38,500,000	-	-	-	-	0.00%	-	0.00%	
5	IPO Expenses	N/A	Vehicle	3,000,000	-	-	-	-	0.00%	-	0.00%	
			Consultancy fee	23,635,200	-	-	-	-	0.00%	-	0.00%	
			Contingencies	17,917,600	-	-	-	-	0.00%	-	0.00%	
			Initial Working Capital	26,915,492	-	-	-	-	0.00%	-	0.00%	
			Sub Total	1,355,228,202	606,132,545	606,132,545	579,326,015	582,609,775	96.12%	23,522,770	3.88%	
Total	Interest on IPO Proceeds in BDT (from FDR & SMD)	N/A	Sub Total	1,360,000,000	1,360,000,000	1,360,000,000	1,360,000,000	1,360,000,000	100.00%	-	0.00%	
			Interest on IPO Proceeds in BDT (from FDR & SMD)	68,291,870	68,291,870	68,291,870	68,291,870	68,291,870	100.00%	-	0.00%	
			Un-Utilized IPO Proceeds with interest income in BDT	4,541,520,162	4,095,015,601	4,095,015,601	4,068,209,071	4,071,492,831	99.43%	23,522,770	0.57%	
			On Behalf of Board	-	-	-	-	-	-	-	-	
			Interest on IPO Proceeds in BDT (from FDR & SMD)	-	-	-	-	-	-	-	-	

On Behalf of Board

Interest on IPO Proceeds in BDT (from FDR & SMD)

Un-Utilized IPO Proceeds with interest income in BDT

On Behalf of Board

Interest on IPO Proceeds in BDT (from FDR & SMD)

Un-Utilized IPO Proceeds with interest income in BDT

On Behalf of Board

Interest on IPO Proceeds in BDT (from FDR & SMD)

Un-Utilized IPO Proceeds with interest income in BDT

On Behalf of Board

Interest on IPO Proceeds in BDT (from FDR & SMD)

Un-Utilized IPO Proceeds with interest income in BDT

On Behalf of Board

Interest on IPO Proceeds in BDT (from FDR & SMD)

Un-Utilized IPO Proceeds with interest income in BDT

On Behalf of Board

*Nagm Afzal Sinha*  
(Nagm Afzal Sinha)  
Chairman

*Munir Rahman Sinha*  
(Munir Rahman Sinha)  
Managing Director

*Tasneem Sinha*  
(Tasneem Sinha)  
Director

*Pinaki & Company*  
Chartered Accountants

Dhaka

Dated: 11 December 2021